Artia Global Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.92M Hold
65,000
0.72% 32
2026
Q1
$3.78M Buy
65,000
+25,000
+63% +$1.15M 0.76% 25
2025
Q4
$1.79M Hold
40,000
0.25% 40
2025
Q3
$1.61M Hold
40,000
0.25% 37
2025
Q2
$1.25M Hold
40,000
0.3% 30
2025
Q1
$1.34M Hold
40,000
0.34% 29
2024
Q4
$1.57M Hold
40,000
0.56% 28
2024
Q3
$1.57M Hold
40,000
0.43% 26
2024
Q2
$1.56M Hold
40,000
0.3% 30
2024
Q1
$1.72M Buy
+40,000
New +$1.84M 0.35% 31

Other funds holding XENE

Artia Global Partners's XENE Position: Q2 2026 in Review

Artia Global Partners held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 65,000 shares worth $3.92M. The position accounts for 0.72% of the portfolio, ranked #32.

Artia Global Partners first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Artia Global Partners held 65,000 shares of Xenon Pharmaceuticals worth $3.92M as of Q2 2026.
  • Artia Global Partners left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 0.72% of Artia Global Partners's portfolio in Q2 2026, its #32 holding.
  • Artia Global Partners first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.